Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
143.6 INR | +0.24% | +1.66% | +3.46% |
Sales 2024 * | 81.13B 972M | Sales 2025 * | 92.97B 1.11B | Capitalization | 190B 2.28B |
---|---|---|---|---|---|
Net income 2024 * | 1.18B 14.11M | Net income 2025 * | 5.06B 60.62M | EV / Sales 2024 * | 2.76 x |
Net Debt 2024 * | 33.7B 404M | Net Debt 2025 * | 27.93B 335M | EV / Sales 2025 * | 2.34 x |
P/E ratio 2024 * |
192
x | P/E ratio 2025 * |
37.6
x | Employees | 6,295 |
Yield 2024 * |
0.14% | Yield 2025 * |
0.35% | Free-Float | 26.56% |
Latest transcript on Piramal Pharma Limited
1 day | +0.24% | ||
1 week | +1.66% | ||
Current month | +11.44% | ||
1 month | +11.44% | ||
3 months | +1.09% | ||
6 months | +55.30% | ||
Current year | +3.46% |
Managers | Title | Age | Since |
---|---|---|---|
Peter DeYoung
CEO | Chief Executive Officer | 46 | 20-03-03 |
Vivek Valsaraj
PSD | President | 51 | 20-06-09 |
Vinay Agrawal
COO | Chief Operating Officer | 60 | 20-04-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 43 | 21-01-03 | |
Neeraj Bharadwaj
BRD | Director/Board Member | 55 | - |
Director/Board Member | 76 | 21-02-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 7 M€ | +1.36% | - | |
0.00% | 117 M€ | -0.10% | - | |
0.00% | 34 M€ | +1.51% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 143.6 | +0.24% | 3,126,412 |
24-04-29 | 143.3 | +0.74% | 3,241,028 |
24-04-26 | 142.2 | +0.21% | 2,286,342 |
24-04-25 | 142 | +2.31% | 2,203,137 |
24-04-24 | 138.8 | -2.32% | 2,992,953 |
Delayed Quote NSE India S.E., April 30, 2024 at 07:42 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.46% | 2.28B | |
+34.00% | 704B | |
+29.29% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+13.79% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- PPLPHARMA Stock